Active Immunotherapy in Leukemia With Neuraminidase-Modified Leukemic Cells*

  • J. G. Bekesi
  • J. F. Holland
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 62)


The enzymic cleavage of the terminal sugar residue from the plasma membrane of neoplastic cells by neuraminidase of vibrio cholerae origin causes a marked increase in immunogenicity of most experimental tumors [1–6, 8–16]. In a DBA/2 leukemia L1210 system, a single leukemic cell is capable of producing leukemia and the ultimate death of the host. However, mice which were immunized with neuraminidase-treated leukemia L1210 cells remained protected against a challenge of 100,000 untreated leukemic cells [1–3]. Repeated injections of neuraminidase-treated leukemia L1210 cells reduced the lethality rate and increased survival of mice with leukemia L1210 tumor grafts [15, 16]. Chemotherapy plus neuraminidase-treated L1210 cells administered in a sequence which preserves the host’s immunobiologically competent cells resulted in the cure of a significant portion of immunized mice [4, 7, 9]. The immunoprotection evoked by the stimulation from the neuraminidase-treated tumor cells was specific for the particular tumor and could be transferred by sera or splenic lymphocytes into unimmunized syngeneic mice [5, 7, 15, 16]. Recently, considerable attention has been directed to combined modality therapy in spontaneous Gross virus-induced leukemia in AkR mice because in many respects AkR leukemia has similar characteristics to the human leukemias.


Acute Myelocytic Leukemia L1210 Cell Acute Myelocytic Leukemia Patient Remission Duration Active Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bagshawe, K. D., Currie, G. A.: Immunogenicity of L1210 murine leukemia cells after treatment with neuraminidase. Nature (Lond) 218, 1254 (1968).CrossRefGoogle Scholar
  2. 2.
    Bekesi, J. G., St. Arneault, G., Holland, J. F.: Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment. Cancer Res. 31, 2130–2132 (1971).PubMedGoogle Scholar
  3. 3.
    Bekesi, J. G., St. Arneault, G., Walter, L., Holland, J. F.: Immunogenicity of leukemia L1210 cells after neuraminidase treatment. J. Natl. Cancer Inst. 49, 107–118 (1972).PubMedGoogle Scholar
  4. 4.
    Bekesi, J. G., Roboz, J. P., Walter, L., Holland, J. F.: Stimulation of specific immunity against cancer by neuraminidase-treated tumor cells. Behring Inst. Mitt. 55, 309–321 (1974).Google Scholar
  5. 5.
    Bekesi, J. G., Roboz, J. P., Holland, J. F.: Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice. Israel J. Med. Sci. 12, 288–303 (1976).PubMedGoogle Scholar
  6. 6.
    Bekesi, J. G., Holland, J. F., Fleminger, R., Yates, J., Henderson, E. S.: Immunotherapeutic efficacy of neuraminidase-treated allogeneic myeloblasts in patients with acute myelocytic leukemia. In: Control of Neoplasia by Modulation of the Immune System. Chirigos, M. A. (ed.). New York: Raven Press, 1977, pp. 573–592.Google Scholar
  7. 7.
    Bekesi, J. G., Roboz, J. P., Holland, J. F.: Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia. Annals of N.Y. Acad. Sci. 277, 313–331 (1976).CrossRefGoogle Scholar
  8. 8.
    Breslow, N. A.: Generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometricka 57, 579–594 (1970).CrossRefGoogle Scholar
  9. 9.
    Holland, J. F., Bekesi, J. G.: Immunotherapy of human leukemia with neuraminidase-modified cells. Med. Clinics of North America 60, 539–549 (1976).Google Scholar
  10. 10.
    Lindenman, J., Klein, P. A.: Immunological aspects of viral oncolysis. Recent advances in cancer research. Berlin: Springer-Verlag, 1967, Vol. IX, p. 66.Google Scholar
  11. 11.
    Rios, A., Simmons, R. L.: Immunospecific regression of various syngeneic mouse tumors in response to neuraminidase-treated tumor cells. J. Natl. Cancer Inst. 51, 637–644 (1973).PubMedGoogle Scholar
  12. 12.
    Rios, A., Simmons, R. L.: Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells. Intern. J. Cancer 13, 71–81 (1974).CrossRefGoogle Scholar
  13. 13.
    Sanford, B. H.: An alteration in tumor histocompatability induced by neuraminidase. Transplantation 5, 1273 (1967).PubMedCrossRefGoogle Scholar
  14. 14.
    Sedlacek, H. H., Meesmann, H., Seiler, F. R.: Regression of spontaneous mammary tumors in dogs after injection of neuraminidase-treated tumor cells. Int. J. Cancer 15, 409 (1975).PubMedCrossRefGoogle Scholar
  15. 15.
    Sethi, K. K., Brandis, H.: Neuraminidase induced loss in the transplantability of murine leukemia L1210 induction of immunoprotection and the transfer of induced immunity to normal DBA/2 mice by serum and peritoneal cells. Br. J. Cancer 27, 106–113 (1973).PubMedCrossRefGoogle Scholar
  16. 16.
    Sethi, K. K., Teschner, M.: Neuraminidase induced immunospecific destruction of transplantable experimental tumors. Postepy Hig. Med. Doswialdczaine 28, 103–120 (1974).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1977

Authors and Affiliations

  • J. G. Bekesi
  • J. F. Holland

There are no affiliations available

Personalised recommendations